Glaukos (GKOS) to Release Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is set to issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81.00 million. During the same period last year, the business posted ($0.53) earnings per share. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Stock Down 2.2 %

Shares of NYSE:GKOS opened at $97.26 on Tuesday. The stock’s 50-day moving average price is $92.52 and its 200-day moving average price is $82.10. Glaukos has a 12-month low of $45.38 and a 12-month high of $103.66. The stock has a market capitalization of $4.88 billion, a P/E ratio of -34.99 and a beta of 1.08. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 434 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Glaukos news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares of the company’s stock, valued at approximately $5,163,644.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $88.25, for a total transaction of $441,250.00. Following the completion of the sale, the director now directly owns 30,620 shares of the company’s stock, valued at approximately $2,702,215. The disclosure for this sale can be found here. Insiders sold 232,881 shares of company stock worth $21,965,491 over the last three months. Company insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on GKOS shares. Truist Financial reaffirmed a “buy” rating and set a $110.00 price objective on shares of Glaukos in a research note on Monday, April 8th. Citigroup raised their price objective on Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Needham & Company LLC raised their price objective on Glaukos from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $99.80.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.